A Bayesian multiparameter model comprising normalized blood tumor mutational burden, CD8 + T cell fraction, and ctDNA dynamics predicted durable clinical benefit with 92% accuracy in both the Discovery and Validation cohorts, and patients with a favorable score had significantly longer PFS. The gene discussed is CD8A; the disease is neoplasm.